Alluvi, known as BI 4744, presents a promising breakthrough in obesity treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates compelling efficacy in https://nanobookmarking.com/story22020189/alluvi-a-detailed-dive-into-the-medication-s-potential